Cardiomyopathy News and Research RSS Feed - Cardiomyopathy News and Research

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.
UVA Health System opens high-tech clinical genomics lab

UVA Health System opens high-tech clinical genomics lab

The University of Virginia Health System has opened a high-tech clinical genomics lab that will personalize care for patients, help doctors determine the best treatments for cancers and other diseases, and allow UVA to offer the most cutting-edge clinical trials. [More]
Sugar-gobbling enzyme helps restore normal function in heart muscles of diabetic rats

Sugar-gobbling enzyme helps restore normal function in heart muscles of diabetic rats

Working with heart muscle cells from diabetic rats, scientists at Johns Hopkins have located what they say is the epicenter of mischief wreaked by too much blood sugar and used a sugar-gobbling enzyme to restore normal function in the glucose-damaged cells of animal heart muscles. [More]
Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 study in children with SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 study in children with SMA

Isis Pharmaceuticals, Inc. today provided an update on children with spinal muscular atrophy (SMA) who have completed the open-label, Phase 2 multiple-dose study of ISIS-SMN Rx and are continuing to receive treatment in an open-label extension (OLE) study. [More]
Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMN Rx in infants with Type I spinal muscular atrophy (SMA). [More]
Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening. [More]
Heart failure patient spearheads Heather Cartwright Inherited Cardiomyopathy and Arrhythmia Project

Heart failure patient spearheads Heather Cartwright Inherited Cardiomyopathy and Arrhythmia Project

Led by internationally-recognized cardiologists who are leaders in their field, the Peter Munk Cardiac Centre today announces the creation of an initiative to break ground in the cause, treatment and ongoing care of patients with an inherited, irregular heartbeat triggered by a rare cardiac structural condition. [More]
Study finds that gene therapy can clip out genetic material associated with heart failure

Study finds that gene therapy can clip out genetic material associated with heart failure

Gene therapy can clip out genetic material linked to heart failure and replace it with the normal gene in human cardiac cells, according to a study led by researchers from the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai. [More]
UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

A UCLA-led study on improving stroke care was selected by the Clinical Research Forum (CRF) as one of the 10 most outstanding research papers written by teams from across the nation in 2014. The organization highlighted the papers at its fourth annual awards ceremony in Washington, D.C. on April 16. [More]
Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001). [More]
Implantable defibrillators help patients with hypertrophic cardiomyopathy live longer

Implantable defibrillators help patients with hypertrophic cardiomyopathy live longer

Newly published research led by the Minneapolis Heart Institute Foundation and Tufts Medical Center in Boston shows that implantable defibrillators (ICDs), along with other modern treatments, have reduced mortality rates and are helping patients with hypertrophic cardiomyopathy (HCM) live longer, including normal life expectancy. [More]
TWi Biotechnology obtains Rare Disease Drug designation in Taiwan for use of AC-203 to treat EBS

TWi Biotechnology obtains Rare Disease Drug designation in Taiwan for use of AC-203 to treat EBS

TWi Pharmaceuticals, Inc. today announced that its fully owned subsidiary, TWi Biotechnology, Inc., has received the designation of Rare Disease Drug by Taiwan FDA for use of AC-203 to treat Epidermolysis Bullosa Simplex (EBS), and is eligible for applying for coverage under National Health Insurance Administration. [More]
Chronic heart failure patients with decreased calcitriol may benefit from aggressive supplementation

Chronic heart failure patients with decreased calcitriol may benefit from aggressive supplementation

In patients with chronic heart failure, the vitamin D metabolite 1,25-dihydroxyvitamin D (1,25(OH)2D), also called calcitriol, and its ratio to parathyroid hormone (PTH 1-84) may help predict cardiovascular death; and patients with decreased calcitriol and decreased ratio of calcitriol to PTH might benefit from more aggressive supplementation, a new study finds. [More]
Discovery demonstrates effect of exercise to prevent chronic health conditions

Discovery demonstrates effect of exercise to prevent chronic health conditions

A researcher at the University of Virginia School of Medicine has magnified a benefit of exercise in mice to provide a "profound" protection from diabetic cardiomyopathy, a potentially deadly heart condition that affects many people with diabetes. The discovery demonstrates the power of exercise to prevent chronic health conditions and suggests that one day some benefits of exercise may come in a pill or bottle. [More]
Understanding heart mutations that cause sudden cardiac arrest

Understanding heart mutations that cause sudden cardiac arrest

New biosciences research at the University of Kent could point the way to greater understanding of the heart mutations that cause sudden cardiac arrest. [More]
Moderate drinking may reduce heart failure risk

Moderate drinking may reduce heart failure risk

Evidence already exists for the beneficial effects of drinking moderate amounts of alcohol on the risk of developing a number of heart conditions; however, the role it plays in the risk of developing heart failure has been under-researched with conflicting results. [More]
Loyola University Medical Center opens center to provide treatments for diseased heart valves

Loyola University Medical Center opens center to provide treatments for diseased heart valves

Loyola University Medical Center has opened a multidisciplinary Valve Center that offers patients a full range of treatments for diseased heart valves. [More]
Study sheds light on how HIV medications cause significant damage to fetal hearts

Study sheds light on how HIV medications cause significant damage to fetal hearts

A study by a Wayne State University and Children's Hospital of Michigan, Detroit Medical Center research team is shedding new light on the troubling question of whether the drugs often given to HIV-positive pregnant women can cause significant long-term heart problems for the non-HIV-infected babies they carry. [More]
Study shows how stem cells can help regenerate damaged muscle after heart attack

Study shows how stem cells can help regenerate damaged muscle after heart attack

Delivering stem cell factor directly into damaged heart muscle after a heart attack may help repair and regenerate injured tissue, according to a study led by researchers from Icahn School of Medicine at Mount Sinai presented November 18 at the American Heart Association Scientific Sessions 2014 in Chicago, IL. [More]
Cardiac stem cell treatment restores heart function damaged by Duchenne muscular dystrophy

Cardiac stem cell treatment restores heart function damaged by Duchenne muscular dystrophy

Researchers at the Cedars-Sinai Heart Institute have found that injections of cardiac stem cells might help reverse heart damage caused by Duchenne muscular dystrophy, potentially resulting in a longer life expectancy for patients with the chronic muscle-wasting disease. [More]
Type 2 diabetes and cardiovascular disease share common risk factors

Type 2 diabetes and cardiovascular disease share common risk factors

Type 2 diabetes (T2D) and cardiovascular disease (CVD) appear to have a lot in common. They share risk factors such as obesity and they often occur together. If they also share the same genetic underpinings, then doctors could devise a way to treat them together too. [More]
Advertisement
Advertisement